2 citations
,
September 2025 in “Frontiers in Pharmacology” In a study using diabetic rats, researchers found that oral empagliflozin accelerated wound healing by reducing inflammation and oxidative stress, indicating potential benefits beyond blood sugar control for managing diabetic wounds.
68 citations
,
January 2022 in “International Journal of Molecular Sciences” This review summarizes factors involved in polycystic ovary syndrome pathogenesis and management, highlights commonly prescribed and repurposed medications, and calls for well-designed clinical trials to evaluate these treatments further.
November 2025 in “Journal of Diabetes Investigation” In this case study, a man with Werner syndrome and diabetes saw improved glycemic control and insulin resistance with dapagliflozin, suggesting its potential usefulness for managing diabetes in similar patients.
April 2026 in “Research Square” This study found that dapagliflozin enhanced mitochondrial quality control and adaptive autophagy in human cardiomyocytes under hypoxic stress, suggesting that these mechanisms may contribute to the cardioprotective effects of sodium-glucose cotransporter 2 inhibitors in ischemic injury.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.